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Objective: Our study was undertaken to clarify the impact of the shear stress-
induced reactive hyperemia (associated with reperfusion) in preconditioning-medi-
ated protection.
Methods: In control rat hearts, a 40-minute preischemic perfusion (constant pres-
sure: 70 mm Hg) period was followed by 25-minute global low-flow ischemia
(constant flow: 0.3 mL/min) and 30-minute reperfusion (constant pressure). As
preconditioning protocol, hearts underwent 2 cycles of 5-minute no-flow ischemia/
5-minute reperfusion.
Results: Although coronary vasodilation in response to shear stress is severely
impaired after global low-flow ischemia and reperfusion, it is fully preserved by
ischemic preconditioning concomitantly with an improvement of left ventricular
developed pressure. Restricting coronary peak flow to 100% of baseline at reper-
fusion reduced left ventricular recovery to the control level. NG-nitro-L-arginine
methyl ester affects the restoration of reperfusion-reactive hyperemia and the
improvement of contractile recovery afforded by ischemic preconditioning. How-
ever, if the time course of hyperemia was restored by forcibly reperfusing to 150%
of baseline for 10 minutes and, therefore, by restricting final peak flow to 80% of
baseline for 20 minutes, contractile function recovered to a high degree despite the
presence of NG-nitro-L-arginine methyl ester.
Conclusion: We conclude that wall stretch and shear stress during reperfusion are
necessary for the mediation phase of preconditioning.
Reactive hyperemia is a well-known phenomenon in which coronaryartery occlusion and subsequent reperfusion elevate the coronaryblood flow above the baseline level determined prior to occlusion.1This vascular reactivity has been investigated extensively and mayinvolve a variety of mechanisms and mediators, including myo-genic relaxation,2 adenosine,3 prostanoids,4 nitric oxide (NO),5
endothelin,6 and adenosine triphosphate (ATP)-sensitive K (KATP) channels.7 Al-
though evaluated at the beginning of reperfusion, this elevation was considered to
be a fundamental indication of the preservation of vessel muscle function. Kuo and
Chancellor8 reported that vascular smooth muscle cells in coronary arterioles can
respond directly to wall stretch caused by change in intraluminal pressure (myo-
genic responses) and that endothelial cells can sense change in blood flow (flow-
mediated responses). However, the consequences of reperfusion depend on the
intensity and duration of the preceding ischemia.9
Several experimental studies have demonstrated that repeated brief coronary
artery ischemia-reperfusion cycles protect the heart from irreversible injury during
subsequent longer episodes of ischemia.10 While most of the experiments showing
this “preconditioning” modeled occlusion-reperfusion using a vascular clamp,
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Ovize and colleagues11 demonstrated this phenomenon us-
ing a coronary cycle flow variation model, which is closer to
human spontaneous unstable angina. Moreover, clinical ev-
idence12 suggests that ischemic preconditioning may be
induced by balloon inflation during percutaneous translumi-
nal coronary angioplasty: the results show that the third
inflation itself produced larger reactive hyperemia while
producing less ischemic responses compared with the first
inflation. Furthermore, it has been effectively reported that
NO and/or adenosine play an important role in ischemic
preconditioning13: this suggests that both ischemic precon-
ditioning and reactive hyperemia may be mediated by com-
mon mechanisms. Two subsequent phases are now recog-
nized in the mechanism of ischemic preconditioning: a
triggering phase and a mediation phase.13 Attention has
been performed on the length of the transient ischemia, the
number of brief ischemia-reperfusion cycles required to
elicit an optimal preconditioning. Some works have been
done on the influence of the delay between the last transient
and sustained ischemia14,15 but few studies have focused on
the correlation between increased reactive hyperemia during
the first minutes of reperfusion and functional recovery of
preconditioned hearts. Others have considered that the pre-
conditioning effect seems to be linked to the repayment of
the flow debt in the perfused rat heart16 and seems to
develop fully only when reflow is complete in the in situ
dog heart.11 We feel that this suggestion is both an impor-
tant and relevant new consideration in the “memory” of
preconditioning.
Therefore, this study was designed to determine the
detailed time course of coronary flow (CF) throughout
reperfusion following global low-flow ischemia in control
and preconditioned hearts. In order to test that NO/cyclic
guanosine monophosphate system may be an important
modulator in the mediation phase of preconditioning, NO
synthesis was blocked by NG-nitro-L-arginine methyl ester
(L-NAME) in some experiments to try to attenuate hyper-
emia during reperfusion. If NO plays a role in precondition-
ing and hyperemia, whether this means that hyperemia is
necessary for preconditioning is the key question. To an-
swer this, groups of hearts with low spontaneous hyperemia
have been forcibly reperfused to give a high hyperemia, and
groups of hearts with high spontaneous hyperemia have
been reperfused at constant restricted flow.
Experimental Procedure
Female Wistar rats (Depre Elevage, BP 70, 18230 St Doul-
chard) weighing 240-300 g, maintained on standard diet
(A04 pellets; UAR, Villemoisson/Orge), were used. The
procedures in this study were in accordance with the guide-
lines and recommendations given by the French “Ministe`re
de l’Agriculture et de la Foreˆt, France,” on the use and care
of animals. All animals were randomly divided into 8
groups.
Isolated Rat Heart Apparatus/Langendorff Perfusion
The isolated Langendorff-perfused rat heart preparation was
used. The rats were anesthetized with sodium pentobarbital
(100 mg/kg intraperitoneal) and then injected with heparin
(1500 UI/kg). Hearts were quickly excised and immersed in
ice-cold Krebs-Henseleit buffer containing (in mM: NaCl
118, KCl 5.6, CaCl2 2.4, MgCl2 1.2, NaHCO3 20, Na2HPO4
1.2, and glucose 11) to stop the contraction at once. Within
1 minute, aortic perfusion (70 mm Hg) was initiated using
the above solution gassed with 95% O2/5% CO2 (pH 7.4) at
37°C. The perfusate did not recirculate. The myocardial
temperature was monitored constantly by a thermistor
probe.
Experimental Protocols
The experimental protocols used are shown in Figure 1 (part
A and part B).
All hearts were perfused for 20 minutes to establish
equilibrium hemodynamics.
(1) In the ischemic control group (CTR, n  6), perfu-
sion was prolonged for 20 minutes. Therefore, hearts
were subjected, via a peristaltic pump (Minipulse 3
pump-Gilson), to a 25-minute global low-flow isch-
emia (at a constant flow of 0.3 mL/min), referred to
as sustained ischemia. During reperfusion, perfusion
pressure again was set at 70 mm Hg for 30 minutes.
(2) Ischemic preconditioned hearts (PC, n  6) were
subjected to two rounds of 5-minute global no-flow
ischemia (GI1 and GI2), each followed by 5-minute
reperfusion (R1 and R2),. This preconditioning pro-
tocol was followed by 25-minute low-flow ischemia
and 30-minute reperfusion with constant pressure
equal to 70 mm Hg.
(3) In the PC/100 group, the preconditioning protocol
was the same as in the PC group, but reperfusion
following low-flow ischemia was performed at a con-
stant flow of 10.8  0.7 mL · min1 · g1 (equal to
100% of the baseline CF) via a peristaltic pump for
30 minutes.
(4) In the PC/150 group, the preconditioning protocol
was the same as in the protocols (2) and (3), but
reperfusion following low-flow ischemia was per-
formed at a constant flow of 16.5  0.5 mL · min1 ·
g1 (equal to 150% of the baseline CF) for 30 minutes.
(5), (6), (7) These three protocols were identical to pro-
tocols (2), (3) and (4) respectively, with in addition,
continuous administration of L-NAME (105 M)
during the 25-minute low-flow ischemia and 30-
minute reperfusion periods.
(8) In the PC/150 80/L-NAME group, the protocol was
the same as in group (7) but, during reperfusion,
constant flow of 150% was performed only for 10
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TABLE 1. Baseline parameters in the different groups of animals
Groups n BW (g) LVDevP (mm Hg) LVEDP (mm Hg) BCF20 (mL · min
1 · g1)
CTR 6 265 13 137 19 5 0.5 11.1 0.8
PC 6 262 9 129 13 4.9 0.4 11.4 0.8
PC/100 6 265 12 143 15 5 0.5 11.1 0.5
PC/150 6 251 9 133 11 5 0.5 10.9 0.4
CTR/LNAME 6 257 14 139 17 5.1 0.5 11.1 1.0
PC/LNAME 6 263 10 141 20 4.9 0.5 10.7 1.1
PC/150/LNAME 6 253 10 131 12 5 0.4 10.9 0.4
PC/150  80/LNAME 6 249 12.5 125 16 5 0.4 11.4 0.7
BW, body weight; LVDevP, left ventricular developed pressure; LVEDP, left ventricular end-diastolic pressure; BCF20, baseline coronary flow at 20 minutes
of the stabilization perfusion.
Figure 1. Schematic diagram of the experimental protocols used. All protocols (part A and part B) included an
initial 20-minute stabilization period (at constant pressure 70 mm Hg), a 25-minute global low-flow ischemia (at
constant flow 0.3 mL/min) followed by a 30-minute reperfusion. In the first group (CTR), initial stabilization perfusion
was prolonged to 40 minutes before low-flow ischemia, reperfusion was at constant pressure. After the 20-min
stabilization period all the preconditioned groups (PC, PC/100, PC/150, PC/L-NAME, PC/150/L-NAME, and PC/15080/
L-NAME) of hearts were subjected to 2 periods of 5-minute global no-flow ischemia (GI1, GI2), each followed by
5-minute reperfusion (R1, R2). In the groups 5 to 8 (B), L-NAME (10
5 M) was added to Krebs-Henseleit buffer during
low-flow ischemia and final reperfusion periods. In group (3), peak flow was restricted to 100% of baseline with
a peristaltic pump throughout reperfusion. In groups (4) and (7), hearts are forcibly reperfused to give a
peak/baseline flow of 150% throughout reperfusion. In group (8), hearts are forcibly reperfused to 150% for 10
minutes and restricted to 80% for 20 minutes.
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minutes, followed by a constant flow equal to 80% of
the baseline CF for 20 minutes.
Functional Measurements
In experiments, a compliant balloon was inserted into the
left ventricle and inflated with water until a ventricular
diastolic pressure of 4-5 mm Hg was recorded. This proce-
dure resulted in systolic pressures of 100-160 mm Hg.
Intraventricular pressure and heart rate were recorded via a
Statham P23 XL pressure transducer.
Peak ischemic contracture was measured as the maxi-
mum rise in left ventricular end diastolic pressure from
baseline values. Peak contracture was expressed as a per-
centage of preischemic left ventricular developed pressure
([LVDevP ] after 20-minute control perfusion).
CF was measured continuously by an electromagnetic
blood flow and velocity meter MDL 1401 (Skalar Medical,
Delft, The Netherlands) and stored on a paper polygraph.
BCF was the baseline CF stabilized at the 20th minute. PCF
was the peak coronary flow at the beginning of reperfusion
and reactive hyperemia (RH  PCF/BCF).
An epicardial electrocardiogram was recorded on a
Gould polygraph throughout the experimental period. Ven-
tricular tachycardia (VT) was defined as a run of four or
more consecutive similar ventricular complexes and ana-
lyzed according to the Lambeth Conventions.17
Electrical Activity
Electrical recordings were obtained with floating glass mi-
croelectrodes filled with 3 M KCl. Transmembrane poten-
tial was measured as the voltage difference between the
intracellular electrode and an Ag/AgCl ground electrode
immersed in the fluid perfusing the heart. As myocardial
action potential duration (APD) is influenced by cell loca-
tion, we studied action potentials (AP) originating from the
middle region of the left or right ventricle. Electrical activity
was displayed on a digital oscilloscope. The duration of the
AP was recorded at 90% repolarization (APD90) using a
Datapac system in a personal computer. Furthermore, VT
was confirmed by the short RR interval and typical action
potential amplitude.
Drugs
These experiments were performed with L-NAME from
Sigma-Aldrich, Saint Quentin Fallavier, France.
Data Analysis
Functional and electrical activities were stored on an IBM
486 computer for subsequent analysis.
All the values were expressed as mean  SEM. Com-
parisons among the different groups were first made by
analysis of variance, and post hoc analysis was done using
the Student-Newman-Keuls test. To compare VT incidence
between the different groups, a 2 test was used.
Results
Baseline Hemodynamic Parameters
No significant differences in left ventricular end-diastolic
pressure, peak developed pressure, and CF were observed
within or between groups during equilibrium periods (Table 1).
Reactive Hyperemia and Duration of Ischemia
The peak CF at the beginning of reperfusion was signifi-
cantly delayed (from 2.3  0.2 to 4.2  0.4 min.) and
reduced (from 19.4  0.4 to 14.1  0.7 mL · min1 · g1)
when the duration of ischemia increased from 5 to 25
minutes (Figure 2). Concomitantly a decrease of LVDevP
recovery (from 99.8  7.2% to 33.3  6.7%) at the end of
reperfusion was observed.
Left Ventricular Pressure
Preconditioning with two short ischemic episodes markedly
restored this LVDevP recovery (93.4  4.6% vs 33.3 
6.7% [Figure 4]) while increasing significantly the peak CF
Figure 2. Coronary reactive hyperemia at the beginning of reper-
fusion after stabilization period and variable durations of global
low-flow ischemia: A, 5 minutes; B, 15 minutes; C, 25 minutes.
Histograms were the LVDevP recoveries, respectively, at the end
of reperfusion. *Significant difference at P < .05 vs (A) group.
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(18.7  0.8 vs 14.1  0.7 mL · min1 · g1) for the same
low-flow ischemia duration. Therefore, the coronary RH
was increased from 127.2 8.5 to 165.6  7.4% (Figure 3,
A). In the PC/100 group, restricting final peak flow to 100%
of baseline (Figure 3, A) throughout reperfusion suppressed
the rise in left ventricular peak developed pressure (Figure
Figure 4. Evolution with time of LVDevP throughout reperfusion following global low-flow ischemia in the control
group (CTR), the preconditioned group (PC) with reperfusion at constant pressure, the preconditioned group with
restricted constant coronary flow during reperfusion (PC100) and the preconditioned group forcibly reperfused at
constant high coronary flow throughout reperfusion (PC 150).
Figure 3. Typical coronary flow traces. A, during the protocols (1) to (4) without drug; B, during the protocols (6)
to (8) with L-NAME throughout global low-flow ischemia and reperfusion. Hearts were forcibly reperfused at
constant coronary flow (150% of baseline in groups 4 and 7) or reperfused with restricted constant coronary flow
(100% of baseline in group 3). In group 8, hearts were forcibly reperfused at 150% for 10 minutes and reperfused
with restricted CF (80%) for 20 minutes.
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4). In addition, if the hearts are forcibly reperfused to give
a peak/baseline flow of 150% (Figure 3, A) throughout reper-
fusion, peak developed pressure decreased drastically in the
PC/150 group compared to that in the PC group (Figure 4).
Concomitantly, significant decreases in left ventricular end-
diastolic pressure were observed between the PC group and the
other three groups during the reperfusion period (Figure 5).
Experiments with L-NAME
CF in the PC/L-NAME group returned only to 117.5% 
5.0% of the preischemic equilibrium level at the beginning
of reperfusion (Figure 3, B), compared to 165.6% 7.4% in
the PC group without L-NAME. Throughout reperfusion,
left ventricular peak developed pressure in the PC/L-NAME
group was significantly lower than that in the PC group, but
no statistically significant differences were shown between
PC/L-NAME, CTR and CTR/L-NAME groups (Figure 6).
In the PC/150/L-NAME group, hearts are forcibly reper-
fused to give a peak baseline flow of 150% (Figure 3, B),
LVDevP recovered only to 32.8% 10.6% (Figure 7) at the
end of reperfusion. In the PC/150  80/L-NAME group,
hearts are forcibly reperfused to give a peak/baseline flow of
150% for 10 minutes followed by 80% for 20 minutes
(Figure 3, B) to mimic the evolution of the CF observed in
the PC group without L-NAME and at constant pressure
(Figure 3, A). Therefore, the rise in left ventricular peak
developed pressure was significantly greater throughout
reperfusion (90.3% 8.6%). In addition, the left ventricular
end-diastolic pressure in the PC/150  80/L-NAME group
showed statistically significant differences from the PC/L-
NAME group only at the end of reperfusion but not from the
PC/150/L-NAME group (Figure 8).
Ventricular Tachycardia
In the control hearts, the overall incidence of VT was 2/6
(Table 2). In the majority of hearts, VT developed within
the first minute of the reperfusion and the mean duration
was 2.5  2.0 minutes. The incidence and duration of VT
were not significantly affected by ischemic preconditioning.
On the contrary, when L-NAME (105 M) was present in
the perfusion fluid during low-flow ischemia and reperfu-
sion, the duration of VT was increased in the CTR/L-NAME
and PC/L-NAME groups, respectively.
Restricting final peak flow to 100% of baseline in the
PC/100 group or forcibly reperfusing the hearts to obtain a
peak/baseline flow of 150% in PC/150 and PC/150/L-
NAME groups give to a rise in incidence and duration of
VT so that arrhythmia persisted in 50% of the hearts at the
end of the reperfusion period. However, in the PC/150 
80/L-NAME group, the duration of VT was significantly
reduced and VT are suppressed at the end of reperfusion in
all hearts.
Discussion
Vasodilator mechanisms were classified as endothelium-
dependent and endothelium-independent18 and endotheli-
um-derived relaxing factor is most likely NO.5 Because
metabolic and myogenic vasodilation can occur without NO
release, they were considered endothelium-independent.19
Figure 5. Evolution with time of left ventricular end-diastolic pressure during global low-flow ischemia and
reperfusion in the control group (CTR), the preconditioned group reperfused at constant pressure (PC), the
preconditioned group reperfused with imposed restricted constant coronary flow (PC 100) and the preconditioned
group forcibly reperfused at constant high coronary flow throughout reperfusion (PC 150).
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The fluid shear stress exerted on the endothelium by the
streaming blood represents the major stimulus for a contin-
uous production of NO in vivo.20 Myogenic contraction
occurs in response to instantaneous increases in transmural
pressure, a response that forms the basis of the autoregula-
tory properties of any given vascular bed. Normally this
response is functionally antagonized by the shear stress-
induced release of NO.21 However, it has been shown that
the vasodilation initiated independently of NO release can,
in turn, increase the shear stress in the vessels, thus inducing
the activation of endothelial NO synthase and prolonging
the duration of vasodilation.22
The restoration of blood flow to a previously ischemic
portion of the myocardium represents an advantage because
substrate and oxygen become available to still viable isch-
emic muscle.23 However, there are disadvantages associated
with reperfusion, including an enhancement of the speed of
necrosis in cells not considered to be viable. Endothelial
dysfunction, if present during myocardial reperfusion, will
represent an additional problem in the reperfusion injury
phenomenon.
The consequences of reperfusion depend on the intensity
and duration of the preceding ischemia. In control hearts,
we have shown that no contracture is observed when the
ischemia time is relatively short (5 minute) while peak
reactive hyperemia is high at reperfusion and recovery of
LVDevP is maximal. However, prolonged ischemia (25
minute) leads to the development of contracture. Conse-
quently, reactive hyperemia is lesser and the recovery of
LVDevP is significantly lower.
Additionally, contracture is increased at reperfusion. Be-
cause the compression of the microvasculature has been
shown to alter transmural perfusion24 this may have con-
tributed to the impairment of CF recovery (low-hyperemia)
during reperfusion. However, in all groups ischemic and
initial reperfusion contracture amplitudes were not signifi-
cantly different from CTR.
Figure 6. Evolution with time of left ventricular developed pressure, throughout reperfusion in the control group
(CTR), the ischemic preconditioned group (PC). Hearts of the CTR/L-NAME and PC/L-NAME groups are perfused with
L-NAME during low-flow ischemia and reperfusion. All hearts are reperfused at constant pressure.
Figure 7. Evolution with time of LVDevP throughout reperfusion in
the preconditioned hearts forcibly reperfused at 150% of baseline
coronary flow for 30 minutes (PC/150/L-NAME) and in the precon-
ditioned hearts first forcibly reperfused at 150% of baseline CF for
10 minutes and secondly reperfused with a restricted coronary
flow (80% of baseline) for 20 minutes (PC/150  80/L-NAME). All
hearts were perfused with L-NAME during low-flow ischemia and
reperfusion.
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Endothelium-derived NO may be involved in reactive
hyperemia following a short duration of coronary no-flow
ischemia while it may be less or may not be involved in
reactive hyperemia following a prolonged ischemia.25,26
However, in a preliminary study,27 we found that coronary
reactive hyperemia following 25-minute global low-flow
ischemia was suppressed by glibenclamide (IKATP inhibi-
tor), was decreased with L-NAME (NO pathway inhibitor)
or methylene blue (guanylate cyclase inhibitor) while the
inhibition of cyclooxygenase with indomethacin failed to
affect this coronary reactive hyperemia. These findings sug-
gest that, in our model, the opening of KATP channel con-
tributes to coronary vasodilation in reactive hyperemia and
that NO may partly be involved.
In the present study, repeated short preischemic hyper-
emia increased the postischemic reactive hyperemia and
thus improved the postischemic functional recovery in iso-
lated rat hearts. Therefore, we have demonstrated that, al-
though coronary vasodilation in response to shear stress is
severely impaired after global low-flow ischemia and reper-
fusion, it is fully preserved by ischemic preconditioning.
This finding indicates that the changes produced in coronary
reactive hyperemia and those presumably induced in pre-
conditioning have the same time course, reinforcing the idea
that the observed changes in preconditioned hearts are me-
diated by changes in CF. In contrast, Kitakaze and col-
leagues28 have shown that coronary hyperemia during
reperfusion was not different in hearts that did or did not
undergo ischemic preconditioning. Moreover, this correla-
tion (hyperemia vs contractile recovery) can be interpreted
in a number of ways—cause and effect. Therefore, we
decided to block hyperemia and see whether this blocked
preconditioning. In 2 groups, we repeated preconditioning
while controlling peak/baseline flow by doing the final
reperfusion at constant flow. Thus, in the PC group, restrict-
ing final peak flow to 100% of baseline have reduced left
ventricular recovery to the control level, demonstrating as
expected that reactive hyperemia is necessary for precondi-
tioning. Moreover, blocking the final reperfusion at constant
high CF (150% of baseline) for 30 minutes reduce drasti-
cally left ventricular recovery, suggesting this consistent
shear stress may be injurious for endothelial cells.
NO is emerging as an important cytoprotective agent and
may play a pivotal role in myocardial protection both as a
trigger and mediator of PC.29 The inhibition of NO synthase
with L-NAME affects the restoration of reperfusion reactive
TABLE 2. Ventricular tachycardia (VT): incidence, dura-
tion, and end
Groups n
VT
Incidence Duration (min) End
CTR 6 2/6 2.5 2.0 0/6
PC 6 1/6 2.0 2.0 0/6
PC/100 6 5/6*† 21.5 5.5*† 5/6*†
PC/150 6 6/6*† 20.0 6.0*† 4/6*†
CTR/L-NAME 6 1/6 5.0 5.0 1/6
PC/L-NAME 6 3/6 11.0 5.0 3/6*†
PC/150/L-NAME 6 4/6† 17.0 6.0*† 3/6*†
PC/150  80/L-NAME 6 4/6† 9.0 4.0 0/6
*P  .05 vs CTR.
†P  .05 vs PC.
Figure 8. Changes with time of left ventricular end-diastolic pressure in the preconditioned hearts forcibly
reperfused at 150% of baseline CF for 30 minutes (PC/150/L-NAME) and in the preconditioned hearts first forcibly
reperfused at 150% of baseline CF for 10 minutes and secondly reperfused with a restricted CF (80% of baseline)
for 20 minutes (PC/150  80/L-NAME), in comparison with preconditioned hearts reperfused at constant pressure
(PC/L-NAME). All hearts received L-NAME continuously during low-flow ischemia and reperfusion.
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hyperemia afforded by ischemic preconditioning. This find-
ing appears to concur with the involvement claimed by
some investigators30 but not with the lack of NO contribu-
tion reported by others31 who have chosen the restoration of
contractility or protection from reperfusion arrhythmia as
end points.
Nevertheless, hyperemia was suppressed by L-NAME
and, concomitantly, LVDevP was significantly reduced in
the PC group. Whether this meant that NO-dependent hy-
peremia but not wall stress was necessary for precondition-
ing was the key question.
Thus, in the PC/150/L-NAME group, when hearts were
forcibly reperfused to give a peak/baseline flow of 150%,
they did not recover to better LVDevP as it would have been
expected. However, if the time course of hyperemia was
restored in the PC/150  80/L-NAME group by forcibly
reperfusing to 150% of baseline only for 10 minutes and by
restricting final peak flow to 80% of baseline for 20 minutes,
therefore, LVDevP recovered to a high degree despite the
presence of L-NAME. An abrupt change in pressure is
probably a response to the rapidly attenuated initial peak CF
that could be due to myogenically mediated vasoconstric-
tion32 confirming a shear stress endothelial dysfunction
relationship.
Finally, the assumption that the changes in the reactive
hyperemia are somehow correlated with the degree of car-
dioprotection give the conclusion that ischemic precondi-
tioning is itself linked with NO-independent vasodilation.
Limitations
The rat isolated heart perfused with crystalloid and oxygen-
ated buffers has its advantages and limitations like any
experimental model. Although the absence of blood cells
can limit the comparison of our results to the one obtained
in vivo, this model provides a valuable tool to study the
local protective mechanisms without any interference with
blood-borne elements: the contribution of the platelet-leu-
kocyte aggregates to the pathobiology of ischemia/reperfu-
sion (I/R) injury is therefore excluded. Moreover, studies33
have shown that crystalloid cardioplegia does not signifi-
cantly affect the endothelium-derived nitric oxide–related
endothelium-dependent relaxation for up to 4 hours. There-
fore, the major cause of injury to endothelium-derived nitric
oxide–related function is due to I/R injury to coronary
endothelial function34 and not due to cardioplegia itself per
se. Despite the improved oxygen-carrying capacity of blood
cells, the absence of hemoglobin which inactivates lumi-
nally released NO is an advantage under the present exper-
imental conditions: findings35 provide evidence that the
endothelial dysfunction observed in hearts undergoing I/R is
due in large part to the reintroduction of oxygen. This
reoxygenation causes a burst of superoxide production early
in the reperfusion period. Endothelial cells, as well as
smooth muscle cells, may serve as the source of these free
radicals because neutrophils and monocytes are not present
in the model.
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